Brain cancer growth halted by absence of protein, study finds

September 20, 2017, Stanford University Medical Center
Experiments by a team of NIH-funded scientists suggests a potential method for halting the expansion of certain brain tumors. Credit: Image courtesy of Michelle Monje, M.D., Ph.D., Stanford University.

The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School of Medicine.

When the signaling molecule neuroligin-3 was absent, or when its signal was interrupted with medication, human cancers called could not spread in the brains of mice, the researchers found.

The study will be published online Sept. 20 in Nature. Graduate student Humsa Venkatesh is the study's lead author.

"We thought that when we put cells into a mouse that was neuroligin-3 deficient, that might decrease growth to some measurable extent. What we found was really startling to us: For several months, these brain tumors simply didn't grow," said Michelle Monje, MD, PhD, assistant professor of neurology and senior author of the study. The findings suggest that interrupting the neuroligin-3 signal could be a helpful strategy for controlling high-grade gliomas in human patients, Monje added.

High-grade gliomas are a group of deadly that include adult glioblastoma, the brain cancer now affecting U.S. Sen. John McCain of Arizona; anaplastic oligodendroglioma; pediatric glioblastoma; and a pediatric tumor called diffuse intrinsic pontine glioma. Five-year survival rates are 60 percent for anaplastic oligodendroglioma, around 10 percent for adult and pediatric glioblastomas and virtually nonexistent for DIPG. New treatments are urgently needed.

Hijacking the normal machinery

The new findings build on prior research published by Monje's team in 2015. At that time, the scientists showed that neuroligin-3 fueled the growth of high-grade gliomas. This was surprising because the protein is a part of the normal machinery of neuroplasticity in a healthy brain, and it is a relatively new concept that cancer can hijack an organ's healthy function to drive cancer growth.

In the new study, Monje's team examined mice that were genetically engineered to lack neuroligin-3. These mice have nearly normal brain function. However, when their brains were implanted with any of the forms of human high-grade glioma, the cancer cells could not proliferate. The growth stagnation persisted for several months.

"Lack of neuroligin-3 doesn't kill the cancer cells; the cells that are there remain there, but they do not grow," Monje said. However, 4½ months after implantation, tumors in some mice circumvented their dependency on neuroligin-3 and began to grow again, she added.

Effect specific to high-grade gliomas

The researchers also tried implanting the brains of mice lacking neuroligin-3 with human . Lack of neuroligin-3 did not affect breast cancer growth, showing that the effect is specific to high-grade gliomas.

The growth-stagnation effects, conserved across different classes of high-grade glioma, were unexpectedly strong. To find out why, the researchers conducted follow-up experiments that examined the cell signals involved in neuroligin-3's role in the division of glioma , which demonstrated that neuroligin-3 activates multiple cancer-promoting signaling pathways and also increases the expression of genes involved in cell proliferation, promotion of malignancy, function of potassium channels and synapse function. The researchers now believe that neuroligin-3 is more than just a gatekeeper of glioma cell division, though further research is needed to clarify its exact role, Monje said.

The team also explored whether blocking neuroligin-3 has therapeutic potential for treating gliomas. Using mice with normal neuroligin-3 brain signaling and human high-grade gliomas, the researchers tested whether two inhibitors of neuroligin-3 secretion could stop the cancers' growth. One of the inhibitors has never been tested in humans, but the other has already reached phase-2 clinical trials as a potential chemotherapy for other forms of outside the brain.

Both inhibitors significantly reduced glioma growth during a short-term trial, suggesting that the strategy of inhibiting neuroligin-3 secretion may help human patients.

'Clear path forward for therapy'

"We have a really clear path forward for therapy; we are in the process of working with the company that owns the clinically characterized compound in an effort to bring it to a clinical trial for brain tumor patients," Monje said. Inhibition of neuroligin-3 will not represent a cure for high-grade gliomas, she cautioned, since it does not kill the . Ultimately, she hopes to combine it with other treatment strategies against the tumors.

"We will have to attack these tumors from many different angles to cure them," Monje said. But given how devastating the tumors are, the possibility of using neuroligin-3 inhibition to slow tumor progression is a hopeful development, she added. "Any measurable extension of life and improvement of quality of life is a real win for these patients."

The team's work is an example of Stanford Medicine's focus on precision health, the goal of which is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.

Explore further: Brain tumor growth stimulated by nerve activity in the cortex, study finds

More information: Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma, Nature (2017). DOI: 10.1038/nature24014

Related Stories

Brain tumor growth stimulated by nerve activity in the cortex, study finds

April 23, 2015
Deadly brain tumors called high-grade gliomas grow with the help of nerve activity in the cerebral cortex, according to a new study by researchers at the Stanford University School of Medicine.

Genetic mutations help brain tumors evade targeting by immunotherapy treatments

March 20, 2017
Tumors of the brain and spinal cord, or gliomas, are among the most commonly occurring brain tumors. Although a majority of gliomas are classified as curable, these low-grade tumors have the potential to develop more aggressive ...

New study shows that genomic profiling can help improve treatment of brain tumors in children

September 14, 2017
The largest genomic profiling study ever conducted into a type of brain tumor known as glioma in children has identified genetic alterations in 96% of cases. As reported in The Oncologist, this genetic information could help ...

Structural insights into the modulation of synaptic adhesion by MDGA for synaptogenesis

July 11, 2017
Synapses connected by various synaptic adhesion molecules are communication spaces between neurons for transmitting information. Among various synaptic adhesion molecules, neuroligins are arguably the most widely studied ...

Key synapse formation regulator identified

August 22, 2017
Professor Ko Jae-won at Korea Advanced Institute of Science and Technology (KAIST) has conducted a study of the three-dimensional structure of proteins that regulate neuronal cell connections for the first time, and has identified ...

Neurons support cancer growth throughout the body

February 13, 2017
Cancer cells rely on the healthy cells that surround them for sustenance. Tumors reroute blood vessels to nourish themselves, secrete chemicals that scramble immune responses, and, according to recent studies, even recruit ...

Recommended for you

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.